



Institut Pasteur
de Montevideo

*Science that changes the future:
Today's Research For Tomorrow's Cures*

Administration Council,
3rd December 2024



AGENDA

1. ACADEMIC ACHIEVEMENTS

- A. SCIENTIFIC & TECHNICAL CAREER
- B. ACADEMIC PROGRAMS & METRICS
- C. STAFF EVOLUTION

2. INNOVATION AND VALORIZATION

3. LAB+




ACADEMIC ACHIEVEMENTS

2024

A. SCIENTIFIC & TECHNICAL CAREER

- *G4 program: with private & institutional (BSE) donations*
 - ✓ *G. Iraola: 2019 – 2022 → 2023 resigned and left the Institut*
 - ✓ *M.E. Francia: 2019 – 2022; 2021-2024 → Consolidated Group*
 - ✓ *G. Moratorio: 2020 – 2023 → Consolidated Group*
 - ✓ *N. Sarute: 2021 – 2024 → New Group Leader Position (USA)*
- *Senior Associate Researchers program: 20 new tenure positions*
 - ✓ *2021: 7 (4 women, 3 men)*
 - ✓ *2022: 5 (4 women, 1 men)*
 - ✓ *2023: 6 (3 women, 3 men)*
 - ✓ *2024: 6 (3 women, 3 men)*
 - ❖ *Resigned: 4 (3 women, 1 men)*

*Distribution by sex of the Associate Researcher Program (2021 - 2024):
total = 24*



■ Women ■ Men

B. ACADEMIC PROGRAMS

INITIATIVES FUNDED
BY DONATIONS
AND EXTERNAL SUPPORT




- Inspire Program
 - Young talent solidarity program
 - Transversal scientific projects
 - Support for international meetings & conferences
 - Visiting Professors Program

<https://youtu.be/YeTmDNHihbo>

ACADEMIC METRICS


PUBLICATIONS	PATENTS	TRAINING	COURSES
1406 (2006 – 2024)	22 (2024)	180 Thesis (2016 -2024)	108 International & Regional Courses (2014 - 2024)

- Scholarships for young female scientists
 - Best theses of the year Awards




SCIENTIFIC PUBLICATIONS (up to 2024)


International Publications



Impact Factor	(n)
≥ 10	9
$\geq 5 - 9.9$	14



C. STAFF EVOLUTION (2010 – 2024)



INNOVATION & VALORIZATION ACHIEVEMENTS

START-UPS CREATED BEFORE LAB+

- EOLO PHARMA
 - ARDAN IMMUNOPHARMA
 - XEPTIVA Therapeutics

EOLO PHARMA INC.



- A **clinical-stage startup** developing innovative therapeutics for obesity through molecular hybridization techniques, combining well-established old drugs with novel, non-conventional anti-inflammatory functional groups.
- Seed money + Round A1/A2 of ~ USD 6 M
- **MVD-1**: Leading compound; a **first-in-class drug for obesity**. Advancing from bench research to Phase 1 (A/B) clinical trial



MVD-1: PRELIMINARY CONCLUSION ON EFFICACY AND SAFETY PROFILE



6:2 Active: Placebo in overweight / obese volunteers for 15 days

MVD-1

1

MVD-1 drives substantial body weight loss in obese patients – losing 2.7% (2.6kg)¹ at the highest dose at day 15


2

All treatment emergent events (TEAs) classified as mild > 80% or moderate with no severe AEs reported

3

No clinically significant or consistent alterations in clinical and safety lab parameters

2-STAGE PHASE 2 ADAPTIVE DESIGN (SINGLE PROTOCOL)



Series B round of investment for approximately USD 50 million

XEPTIVA THERAPEUTICS

- The world's first active immunization for chronic conditions.
- Recombinant multi-target immunogens based in Multiple Isomeric Epitopes targeting neurogenic inflammation.
- Currently running a clinical trial (Dogs) for the treatment of pain associated with canine osteoarthritis.

XEPTIVA THERAPEUTICS

- **Business case:**
 - ✓ Round A ~ USD 2.5 M
 - ✓ Scientific founder team full time for the start-up (resigned from their positions at the institute)
 - ✓ IP transferred to the start-up.
 - ✓ Start-up is incubated at the Institut Pasteur de Montevideo, contracting technical services and labs.
 - ✓ Institut Pasteur de Montevideo will receive 7.5 % of future earnings.

START-UPS CREATED BY LAB+

➤ 2024

- B₄-RNA
 - SCAFFOLD BIOTECH
 - GUSKA
 - LoCBio

➤ 2025

2ND INTERNATIONAL CALL FOR DISRUPTIVE SCIENTIFIC PROJECTS IN BIOMEDICINE OR NEW START-UPS

52 applications:

32 Scientific/Innovative Projects
20 Startups in Life Sciences

Requested investment:

USD 150 K to 2.5 M

Verticals:


Animal Health
Human Health – Diagnosis & Therapeutic
Environmental Health
AgTech & Food Tech

Countries:



2ND INTERNATIONAL CALL

Selection process





AC. PROF. EC. CARLOS STENERI
(19 Dec. 1945 – 14 Nov. 2024)

THANK YOU, MERCIE, GRACIAS